{
    "name": "iopamidol",
    "comment": "Rx",
    "other_names": [
        "Isovue",
        "Scanlux"
    ],
    "classes": [
        "Iodinated Contrast Media"
    ],
    "source": "https://reference.medscape.com/drug/isovue-scanlux-iopamidol-343763",
    "pregnancy": {
        "common": [
            "Pregnancy Category: B",
            "Lactation: Excretion into breast milk unknown; not recommended"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Excretion into breast milk unknown; not recommended"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Not for intrathecal use"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitvity to product or components",
                "Intrathecal injection concurrently with intrathecal corticosteroid administration (significant bacterial infection)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Before examination patients should be well hydrated to prevent contrast associated nephropathy",
                "Caution in patients with seizures, thromboembolic diseases including IM and stroke, chronic alcoholism, heart failure, hepatorenal insufficiency, hyperthyroidism, multiple myeloma, pheochromocytoma, renal disease, sickle cell disease",
                "Serious adverse events reported from inadvertent intrathecal administration of iodinated contrast that is not indicated for intrathecal use (Isovue and Isovue Miltipack are not for intrathecal administration)",
                "Severe cutaneous adverse reactions (SCAR) may develop from 1 hour to several weeks after intravascular contrast agent administration; these include Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS); reaction severity may increase and time to onset may decrease with repeat administration of contrast agent; prophylactic medications may not prevent or mitigate severe cutaneous adverse reactions; avoid administering therapy to patients with a history of a severe cutaneous adverse reaction to the drug"
            ],
            "specific": [
                {
                    "type": "Thyroid dysfunction in pediatric patients",
                    "description": [
                        "Thyroid dysfunction characterized by hypothyroidism or transient thyroid suppression reported after both single exposure and multiple exposures to iodinated contrast media in pediatric patients 0 to 3 years of age",
                        "Advise parents/caregivers about risk of developing thyroid dysfunction after therapy; advise parents/caregivers when to seek medical care for their child to monitor for thyroid function",
                        "Younger age, very low birth weight, prematurity, underlying medical conditions affecting thyroid function, admission to neonatal or pediatric intensive care units, and congenital cardiac conditions are associated with increased risk of hypothyroidism after ICM exposure",
                        "Pediatric patients with congenital cardiac conditions may be at greatest risk given that they often require high doses of contrast during invasive cardiac procedures, such as catheterization and computed tomography (CT)",
                        "An underactive thyroid during early life may be harmful to cognitive and neurological development and may require thyroid hormone replacement therapy",
                        "After exposure to iodinated contrast media, individualize thyroid function monitoring in pediatric patients 0-3 years of age based on underlying risk factors, especially in term and preterm neonates",
                        "Pediatric patients at higher risk of experiencing adverse events during contrast medium administration may include those having asthma, a sensitivity to medication and/or allergens, cyanotic heart disease, congestive heart failure, serum creatinine greater than 1.5 mg/dL or <12 months of age"
                    ]
                },
                {
                    "type": "FDA MedWatch",
                    "description": [
                        "March 30, 2022: ",
                        "FDA",
                        " recommended newborns and children aged â‰¤3 years have follow-up thyroid monitoring within 3 weeks after receiving iodinated contrast media (ICM) for X-rays and other medical imaging procedures ",
                        "Published studies found underactive thyroid and temporary decreases in thyroid hormone levels were uncommon; however, if identified and treated early, future complications may be prevented ",
                        "Appropriately monitor for signs and symptoms of hypothyroidism and decreased thyroid hormone levels following ICM exposure; consider evaluating thyroid function within 3 weeks, especially in term and preterm neonates and children with some underlying conditions ",
                        "If thyroid dysfunction detected, treat and monitor thyroid function as needed to avoid future complications ",
                        "Certain pediatric patients are at increased risk, including newborns or have very low birth weight, prematurity, or presence of cardiac or other conditions (eg, requiring care in neonatal or pediatric ICUs) ",
                        "Patients with cardiac conditions may be at greatest risk since they often require high doses of contrast during invasive cardiac procedures "
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Hot flashes",
            "percent": "3.4"
        },
        {
            "name": "Angina pectoris",
            "percent": "3"
        },
        {
            "name": "Flushing",
            "percent": "1.8"
        },
        {
            "name": "Bradycardia",
            "percent": "1.3"
        },
        {
            "name": "Hypotension",
            "percent": "1"
        },
        {
            "name": "Hives",
            "percent": "1"
        },
        {
            "name": "Cyanotic heart disease",
            "percent": null
        },
        {
            "name": "Right ventricular abnormalities",
            "percent": null
        },
        {
            "name": "Abnormal pulmonary circulation",
            "percent": null
        },
        {
            "name": "Skin necrosis",
            "percent": null
        },
        {
            "name": "e",
            "percent": null
        },
        {
            "name": "g",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "urticaria and skin discoloration",
            "percent": null
        },
        {
            "name": "Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome and toxic epidermal necrolysis",
            "percent": null
        },
        {
            "name": "SJS",
            "percent": null
        },
        {
            "name": "TEN",
            "percent": null
        },
        {
            "name": "acute generalized exanthematous pustulosis",
            "percent": null
        },
        {
            "name": "AGEP",
            "percent": null
        },
        {
            "name": "and drug reaction with eosinophilia and systemic symptoms",
            "percent": null
        },
        {
            "name": "DRESS",
            "percent": null
        },
        {
            "name": "Hyperthyroidism",
            "percent": null
        },
        {
            "name": "hypothyroidism",
            "percent": null
        }
    ]
}